A Prospective Study to Examine the Need to Adjust the Dose of Apixaban When Used in Atrial Fibrillation and Obesity

A prospective cohort study to determine whether a high body weight (BMI equal to or greater than 35 kg / m 2) has an effect on anticoagulant Apixaban level in the blood of patients with atrial fibrillation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Anticoagulant Apixaban Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

HaEmek Medical Center

Afula, 18101, Israel

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

hospitalized Patients on Steady State level of Apixaban, based on the data given in the hospital ward . A level of Steady State is received within two days of treatment.

Exclusion criteria

Anasarca
acute renal failure

Treatment and study plan

Anti Xa levels

Diagnostic Test

one Blood sample

Primary outcomes

Anti Xa level of patients with atrial fibrillation and obesity while treatment of Apixaban.

Time frame: 6 month

Sponsors and collaborators

Lead sponsor

HaEmek Medical Center, Israel

Other

Registry information

Official study title

A Prospective Cohort Study to Examine the Need to Adjust the Dose of Anticoagulant Apixaban When Used in Patients With Atrial Fibrillation and Obesity

Important dates

Study start: 2019
Primary completion: 2020
Study completion: 2020
First posted: Mar 28, 2019
Registry last updated: Apr 1, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed